The Missing Asset: Does Wellbeing Actually Own the Science It Is Selling?

The Men Behind Wellbeing — Chapter Nine

Lydac Neuroscience once held patent rights over Stephen Ray's microvesicle technology. Lydac subsequently entered insolvency and has now been dissolved. Today, Wellbeing International Foundation promotes a Cell-Free Therapy built around extracellular vesicles and is raising investment to support its research and expansion. If these technologies share the same scientific lineage, one question becomes unavoidable: where did the intellectual property come from—and what does Wellbeing actually own?

For the last several chapters, this investigation has gone backwards.

That was deliberate.

We started with Wellbeing International Foundation.

Then we followed Stephen Ray.

Ray led us to patents.

The patents led us to Lydac Neuroscience Limited.

Lydac led us to Andrew Chancellor.

And Chancellor's directorship took us into the insolvency of a biotechnology company that once held intellectual property associated with Ray's microvesicle research.

But it is time to remember why we started following this trail in the first place.

This investigation is not really about an old British company that failed several years ago.

It is about Wellbeing International Foundation today.

It is about a company promoting Cell-Free Therapy to patients.

It is about a company that publicly describes extracellular vesicles as a fundamental component of that therapy. (Wellbeing International Foundation)

And increasingly, it is about a company accepting investment capital to fund its research programme and international expansion. (Wellbeing International Foundation)

That changes the importance of everything we have uncovered.

Because if the science being presented today descends from technology originally developed by Stephen Ray and owned by Lydac Neuroscience, then we need to answer a very simple question.

How did it get from Lydac to Wellbeing?

And there is an even more important question behind it.

Does Wellbeing actually own it?

What Wellbeing Says Its Therapy Contains

Let's begin with Wellbeing's own description.

Wellbeing currently describes Cell-Free Therapy as taking a patient's blood, isolating white blood cells and placing them under controlled conditions before returning a concentrated preparation containing:

extracellular vesicles;

growth factors;

and:

cytokines.

Wellbeing describes the treatment as autologous, meaning the biological material originates from the patient who ultimately receives it. (Wellbeing International Foundation)

On its science pages, Wellbeing places considerable emphasis on extracellular vesicles.

It describes them as tiny membrane-bound packages released by cells that carry biological material including proteins and RNA. (Wellbeing International Foundation)

Now compare that with the intellectual property we have been investigating.

What Stephen Ray's Patent Describes

The European patent EP2240189B1 is titled:

Microvesicles.

Stephen Ray is named as inventor.

Lydac Neuroscience Limited is identified as both the original assignee and the current assignee displayed in the patent record.

The patent describes methods for producing microvesicles, particularly immunologically matched autologous microvesicles, for potential therapeutic, cosmetic and other applications. (Google Patents)

Read those two descriptions again.

Wellbeing today:

autologous biological material containing extracellular vesicles.

Ray's earlier patent:

autologous microvesicles with potential therapeutic applications.

There is an obvious conceptual relationship.

But an investigation cannot stop at resemblance.

Similarity Is Not Proof of Identity

This is where we need to be extremely precise.

I am not stating that EP2240189B1 is the patent covering Wellbeing's current Cell-Free Therapy.

We have not established that.

Microvesicles and extracellular vesicles are overlapping scientific concepts, but modern EV terminology and manufacturing methods have evolved considerably.

Wellbeing's present process may incorporate later discoveries.

There may be additional intellectual property.

There may be proprietary manufacturing know-how that was never patented.

There may be licences.

There may be entirely new patent families.

And the actual claims of Ray's older patents may not cover every aspect of today's CFT.

Those possibilities need to be investigated.

But there is now enough documentary overlap to ask a much stronger question:

What is the precise relationship between Stephen Ray's Lydac-era microvesicle technology and Wellbeing's present Cell-Free Therapy?

Wellbeing Itself Places Stephen Ray at the Centre of the Science

This isn't a connection I am manufacturing.

Wellbeing itself identifies Stephen Ray as its Senior Scientific Consultant and says he has more than 30 years of academic and commercial research experience in cell therapy. (Wellbeing International Foundation)

That scientific history is part of Wellbeing's credibility story.

Ray is therefore not an irrelevant scientist who happened to work on similar technology decades ago.

He is part of Wellbeing's present scientific leadership.

And we now know that his earlier intellectual-property history includes patents involving precisely the type of extracellular biological material that appears central to Wellbeing's current therapy. (Justia Patents)

That makes the ownership question legitimate.

The Patent Wasn't Originally Wellbeing's

One fact is clear.

The European patent record does not identify Wellbeing International Foundation as the original assignee.

It identifies:

Lydac Neuroscience Ltd. (Google Patents)

That company was incorporated in 2007 as a biotechnology research company.

Stephen Ray was one of its early directors.

Andrew Chancellor later became a director.

And Lydac ultimately entered administration, proceeded into creditors' voluntary liquidation and was dissolved on 9 April 2025. (Companies House)

Yet the scientific story continued.

Today Ray is at Wellbeing.

Chancellor is at Wellbeing.

And extracellular vesicles are at the centre of Wellbeing's Cell-Free Therapy story.

So where is the legal bridge?

Where Is the Assignment?

This is perhaps the single most important document we need to find.

If Lydac owned the relevant intellectual property and that intellectual property eventually became part of Wellbeing, there are several possible mechanisms.

The patents could have been assigned.

They could have been sold.

They could have been licensed.

A successor company could have acquired them.

Another entity could have acquired the technology and subsequently licensed it to Wellbeing.

Or the older patents may no longer be commercially relevant because Wellbeing uses later technology.

Any of those explanations could be perfectly legitimate.

But they lead to very different conclusions.

And at present, the public records I have reviewed do not establish which explanation applies.

Something in the Patent Record Is Particularly Interesting

The current Google Patents record for EP2240189B1 still displays:

Current Assignee: Lydac Neuroscience Ltd

and:

Original Assignee: Lydac Neuroscience Ltd.

At the same time, its legal status is displayed as:

Not-in-force. (Google Patents)

Google itself warns that its assignee and legal-status information may be inaccurate and should not be treated as a legal conclusion.

That warning matters.

This is therefore not proof that Lydac remained the legal owner until dissolution.

But equally, this search has not yet produced a public assignment record showing the European patent moving from Lydac to Wellbeing.

That absence is important enough to investigate further.

A Dissolved Company Cannot Explain the Present-Day Commercial Structure

Lydac no longer exists.

Companies House records the company as dissolved on 9 April 2025. (Companies House)

So if commercially important technology once belonging to Lydac remains relevant today, something must explain its present position.

Perhaps the rights expired.

Perhaps they lapsed.

Perhaps they were transferred.

Perhaps another company bought them.

Perhaps Wellbeing licensed related technology independently.

Perhaps today's CFT is sufficiently different that those patents simply no longer matter.

But we should be able to determine which.

Because intellectual property is not corporate folklore.

It has legal ownership.

This Is Where the Investment Story Becomes Important

If Wellbeing were merely discussing experimental science, this might remain an interesting historical question.

But Wellbeing is raising money.

In March 2026, Wellbeing announced that it had closed the opening tranche of its current capital round.

The company says the round remains open.

It says the capital supports continued research, expansion of its clinical-relationship network in the United States and Europe, documentation work and operating capacity.

Wellbeing also says that historically it has been funded through a combination of:

private investment;

patient revenue;

and:

selective philanthropy. (Wellbeing International Foundation)

That makes intellectual-property ownership potentially material to investors.

What Exactly Is an Investor Investing In?

This is where the investigation returns to one of its original concerns.

A prospective investor hearing about decades of research, proprietary biological technology and Cell-Free Therapy could reasonably believe that the organisation receiving their investment controls commercially valuable scientific assets.

But what precisely are those assets?

Does Wellbeing own patents?

Does another company own them?

Does Wellbeing have exclusive licences?

Does it rely primarily upon scientific know-how?

Does it own proprietary manufacturing processes?

Are there newer patents that we haven't yet identified?

What prevents another organisation from replicating the process?

And perhaps most importantly:

What intellectual property is actually owned by the entity into which investors are putting their money?

Those are basic biotechnology investment questions.

The Difference Between Science and Ownership

This distinction needs to be understood clearly.

Stephen Ray may have invented technology.

That does not automatically mean Stephen Ray owns it.

Stephen Ray may work with Wellbeing.

That does not automatically mean Wellbeing owns his earlier intellectual property.

Andrew Chancellor may previously have directed the company that held patents.

That does not automatically transfer those patents to another organisation he later leads.

And Wellbeing may legitimately use technology related to Ray's earlier research.

That still does not tell us the legal mechanism through which it obtained those rights.

These are different things:

inventorship;

ownership;

licensing;

commercial use;

and:

scientific expertise.

They should not be blurred together.

There Is Another Possibility Investors Need to Consider

What if Wellbeing does not need the old patent?

That is entirely possible.

The European patent record currently describes EP2240189B1 as not in force. (Google Patents)

If the technology is now outside effective patent protection—or if today's CFT falls outside those particular claims—Wellbeing might instead rely upon:

trade secrets;

manufacturing know-how;

laboratory protocols;

later inventions;

data;

branding;

clinical relationships;

or newer intellectual property.

That would not inherently be a problem.

But it would change the investment proposition.

An investor needs to understand whether the competitive advantage is:

patent-protected technology

or:

proprietary know-how without equivalent patent protection.

Those are very different assets.

What Does Wellbeing Publicly Say About Ownership?

This is another area requiring scrutiny.

Wellbeing's public website contains a standard intellectual-property statement saying that its website content—including text, graphics, logos, images and software—is its property or that of its content suppliers. (Wellbeing International Foundation)

But website copyright is not the question we are asking.

We are asking about the underlying biotechnology.

In the public materials reviewed for this chapter, I have not found a clear statement identifying the patent numbers Wellbeing says protect CFT or a public explanation of the ownership/licensing chain connecting Ray's historical intellectual property to the current organisation.

That does not mean such agreements do not exist.

Private biotechnology companies routinely keep commercial agreements confidential.

But when investment is being sought, those documents become exactly the sort of material sophisticated investors should expect to examine during due diligence.

The Investors Should Ask for the IP Schedule

This is where the investigation can become very practical.

Anyone seriously considering investing in Wellbeing should ask to see an intellectual-property schedule identifying:

the relevant patents;

patent applications;

registered owners;

beneficial owners;

licences;

territories;

expiry dates;

royalty obligations;

trade secrets;

manufacturing know-how;

and any intellectual-property agreements involving Stephen Ray or predecessor organisations.

They should also ask a simple question:

Which legal entity owns Cell-Free Therapy?

Not the website.

Not the brand.

Not the scientific story.

The actual technology.

And Then Ask About Lydac

If the answer involves technology developed by Stephen Ray, the next question should be:

What relationship does that technology have to the intellectual property previously held by Lydac Neuroscience?

If there is no relationship, that can presumably be explained.

If the old patents are irrelevant, that can be demonstrated.

If the technology was transferred, there should be documentation.

If it was licensed, there should be a licence.

If new intellectual property superseded it, there should potentially be later filings or documentation identifying that development.

Any of those answers could resolve the issue.

What matters is transparency.

Patients Also Deserve an Answer

This is not solely an investor issue.

Patients are being presented with a treatment Wellbeing says concentrates their own regenerative signalling material, including extracellular vesicles, growth factors and cytokines. (Wellbeing International Foundation)

The historical provenance of that technology therefore matters.

How long has this particular process existed?

When was it developed?

What changed from Ray's earlier microvesicle work?

Which parts of the current therapy are genuinely new?

How many generations of the technology have existed?

What evidence accompanied each development?

Those questions help patients distinguish between a long scientific history and a long history of evidence supporting the exact treatment they are purchasing.

They are not the same thing.

“30 Years of Research” Needs Context

Wellbeing currently promotes a long scientific heritage around CFT and identifies Ray as having more than 30 years' experience in cell therapy research. (Wellbeing International Foundation)

That history may be entirely genuine.

Indeed, the patent evidence we've uncovered supports the fact that Ray has a substantial historical footprint in relevant biological research.

But that creates an important distinction.

Thirty years of a scientist's research experience is not necessarily thirty years of research on the exact commercial therapy being sold today.

The two should not be confused.

If CFT evolved from earlier microvesicle technology, then showing that evolution would actually strengthen Wellbeing's scientific story.

But it would also allow patients and investors to see precisely where the modern product begins.

We Need to Follow Two Trails Now

From this point, the investigation divides into two documentary trails.

The Patent Trail

We need to establish the complete ownership history of Ray's microvesicle patent family.

Not simply who originally filed it.

We need assignments.

Changes of proprietor.

Licences where publicly discoverable.

National patent status.

Expiry and lapse dates.

And any successor applications.

The Wellbeing Trail

Separately, we need to establish what intellectual property Wellbeing says it currently owns or controls.

Patents.

Applications.

Licences.

Proprietary manufacturing processes.

Laboratory agreements.

Scientific know-how.

And the entity actually receiving investment.

Then—and only then—can the two trails legitimately be connected.

There May Be a Completely Innocent Explanation

This needs saying clearly.

We may ultimately discover that Wellbeing has perfectly valid ownership or licensing arrangements.

We may discover that the Lydac patents became irrelevant years ago.

We may discover that today's CFT represents later technology that falls outside those patents.

We may discover that newer intellectual property replaced the earlier work.

We may even discover that Wellbeing deliberately chose not to pursue patent protection for aspects of CFT because disclosure through patents would reveal commercially sensitive processes.

All of those possibilities exist.

The purpose of an investigation is not to decide the answer first.

It is to find it.

But Until We Find the Bridge, the Question Remains

What we have established is already significant.

Stephen Ray developed microvesicle-related intellectual property.

Lydac Neuroscience was the applicant and recorded assignee on important parts of that patent family. (Justia Patents)

Ray was a director of Lydac. (Companies House)

Andrew Chancellor subsequently became a director of Lydac.

Lydac entered insolvency and was eventually dissolved. (Companies House)

Today Ray and Chancellor are associated with Wellbeing.

Wellbeing promotes a therapy whose own description places extracellular vesicles at the centre of its biological mechanism. (Wellbeing International Foundation)

And Wellbeing is accepting private investment to fund its continuing research and expansion. (Wellbeing International Foundation)

Those are the documented pieces.

What we have not yet found is the bridge between them.

Conclusion: Show Us the Chain of Ownership

After eight chapters, I think the central question can now be stated very simply.

If Wellbeing's Cell-Free Therapy is substantially derived from the same scientific technology Stephen Ray developed during the Lydac era:

Where did Wellbeing get it?

If Wellbeing owns the intellectual property:

show the ownership chain.

If it licenses the technology:

identify the licensing structure.

If the old patents are irrelevant:

explain what replaced them.

If CFT represents genuinely new technology:

show where the new development begins.

And if the commercial value offered to investors depends upon proprietary scientific assets:

identify exactly which entity owns those assets.

None of those requests accuses Wellbeing, Andrew Chancellor or Stephen Ray of wrongdoing.

They ask for something much simpler.

Transparency.

Because Lydac Neuroscience has disappeared.

The patent record survives.

The scientist survives.

The businessman survives.

The technology appears, at minimum, scientifically related.

And a new organisation is now asking patients and investors to put money behind Cell-Free Therapy.

Until the ownership trail is established, one question remains at the centre of this investigation:

Does Wellbeing International Foundation actually own the science it is selling—or what, precisely, does it own?

Next: Chapter Ten — The Patent Trail: From Lydac to Wellbeing

We now know what needs proving. Chapter Ten follows the individual patent-family records across jurisdictions, searches for assignments and successor rights, and compares the actual patent claims with Wellbeing's current description of Cell-Free Therapy. If the technology moved, we want to know when, how, to whom—and where the documentary evidence is.